加拿大视角：单克隆抗体在有血液系统恶性肿瘤的脆弱患者中 COVID-19 暴露前和暴露后的预防保护作用。
A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
机构信息
Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB T2N 4Z6, Canada.
Division of Hematology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
出版信息
Curr Oncol. 2022 May 31;29(6):3940-3949. doi: 10.3390/curroncol29060315.
Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab-imdevimab, and bamlanivimab have provided valuable options for the treatment of COVID-19 disease. More recently, monoclonal antibodies have been examined for the prevention of COVID-19 infection. The monoclonal antibody combination, tixagevimab-cilgavimab, was recently approved by Health Canada as pre-exposure prophylaxis against COVID-19 in individuals who are immunocompromised or where vaccination is not recommended. Prophylactic approaches such as the use of tixagevimab-cilgavimab, in addition to COVID-19 vaccination, may provide additional protection for patients with hematological malignancies who are at greater risk of serious outcomes from COVID-19 infection.
血液系统恶性肿瘤患者在感染 COVID-19 后出现严重后果的风险增加，这表明除了接种疫苗外，还需要更广泛的保护。索托维单抗、卡瑞利珠单抗-西米普利单抗和巴尼利珠单抗等单克隆抗体为 COVID-19 疾病的治疗提供了有价值的选择。最近，单克隆抗体也被用于预防 COVID-19 感染。单克隆抗体联合制剂 tixagevimab-cilgavimab 最近被加拿大卫生部批准用于免疫功能低下或不建议接种疫苗的人群 COVID-19 暴露前预防。除 COVID-19 疫苗接种外，预防性方法，如使用 tixagevimab-cilgavimab，可能为感染 COVID-19 后出现严重后果风险较高的血液系统恶性肿瘤患者提供额外保护。
Zotero 插件